Gynecologic malignant neoplasms are a severe health problem among female patients, of which cervical cancer (CC), in particular, is a common disease leading to high mortality rates. Despite extensive attempts by researchers to solve the molecular mystery of CC, the mechanisms of its pathogenesis remain unclear. Tumor markers used in the clinical laboratory, such as squamous cell carcinoma (SCC), cancer antigen (CA)-125, and CA19-9, provide some help in diagnosing patients with CC. However, finding new molecular markers with high sensitivity and specificity is necessary. This review focuses on the role of epigenetic changes, particularly microRNAs (miRNAs), to CC. Several miRNAs that associated with CC potentially have the advantage of being early biomarkers. Moreover, altered serum miRNAs or single nucleotide polymorphisms in miRNA patterns may predict disease progression.
stage of CC usually show no symptoms. When the cancer grows larger, patients may notice 1 or more of the following symptoms: vaginal bleeding, pelvic pain, unusual vaginal discharge, and pain during sexual intercourse. Therefore, reliable screening and diagnosis methods could decrease the number of patients who will develop invasive CC.
Previously, epigenetic changes including DNA methylation, histone modification, and microRNAs (miRNAs) have shown a role in cancer development. 13 miRNAs that are overexpressed in cancer may function as oncogenes. miRNAs with tumor suppressor activity in normal tissue may be downregulated in cancer. 14, 15 Tissue and cell lineage specificity with miRNA expression patterns has provided insight into pathognomonic information. 16 Not only miRNAs but also miRNA-associated single nucleotide polymorphisms (miRSNPs) influence individual susceptibility to cancer. In this review, we focused on alteration of miRNA expression in CC as the most promising avenue of CC-marker development.
Natural History of HPV Infection and CC Progression
HPV is a member of the Papovvairidae family; it is a small, nonenveloped virus. The HPV genome consists of circular double-stranded DNA with a size of approximately 8 kilobases (kb). 17 It is divided into 3 functional regions: an early region (E), a late region (L), and a long control region (LCR). The LCR shows the highest variation of viral genome expression. Expression of the early region, which includes E1, E2, E4, E5, E6, and E7 genes, may reflect the period of infection. The late region is composed of genes for structural capsid proteins such as L1 and L2. HPVs associated with genital tract cancer can be separated into 2 groups.
The first group is the low-risk HPV types, including types 6, 11, 42, 43, and 44. The second is the high-risk HPV (HR-HPV) types, including types 16, 18, 31, 33, 34, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 70. 18 Normally, the HPV E2 protein has a role as a transcriptional repressor for oncogenes. During HPV integration into the host genome, E2 is disrupted. The loss of E2 gene expression promotes E6 and E7 oncoprotein production, leading to inactivation of tumor suppressors. E6 binds to p53 tumor suppressor, whereas E7 binds to retinoblastoma tumor suppressor (pRB), causing dysregulation of the cell cycle, uncontrolled cell proliferation, and also increased cell survival. 19 The pathogenesis of CC is started by transmission of HPV to basal epithelial cells during sexual activity and genital skin-to-skin contact. Normally, 70% of these viral infections resolve spontaneously, and in 90% of cases, the viruses are naturally cleared within 2 years by the immune system. However, HPV has several immune evasion mechanisms, including that the viral life cycle occurs entirely within epithelial cells; that there is no viremia, no cell death, and no inflammation; and that viral proteins cause local immunosuppression. HPV induces cells to proliferate and expand laterally. Cervical carcinogenesis is a slow-growing type of cancer triggered by HPV. If HPV infection is persistent, lasting 1 to 20 years, normal cervical tissue will be transformed into a precancerous lesion or lesions, including cervical intraepithelial neoplasia (CIN) I, II, and III, and eventually into invasive cancer.
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Current CC Screening Test
The Papanicolaou test (Pap test) is a cytology test of cells collected from the cervix, used to find abnormal cells before they develop into cancer. The Pap test applies conventional cytologic techniques to identify precancerous cells. If cancerous cells are detected early, the patient will be cured. However, the Pap test has low sensitivity 22 and low accuracy, 23 partially due to collection of inadequate specimens.
Certain HPV types are well-known as being high-risk oncogenic agents. So, HPV-DNAs that can distinguish these high-risk types have been developed to increase screening performance via the L1 gene in DNA fragment detection. 24 The L1 gene is encoded for the major capsid protein of HPV. 25, 26 Also, the expression level of E6/E7 mRNA 27 that related to cell integration and transformation to invasive CC has been developed as a prognosis marker. 28, 29 Currently, HPV-DNA testing is approved by the United States Food and Drug Administration (FDA) as the primary screening test for CC. 30 However, approximately 20% of patients who were screened using only the HPV test are misdiagnosed. 31 Recently, Tracht J et al 32 suggested that cytology testing can lessen that rates of false-negative results from HPV testing by observation of lesion characteristics. Therefore, the combination of Pap testing and HPV testing is a more sensitive screening method than using the HPV test or Pap test only. Further, colposcopy is still an essential part of confirmatory testing to find the abnormal cells before colposcopic biopsy.
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Finding molecular markers associated with CC ( Figure 1 ) is challenging but necessary due to the limitations of the Pap and HPV-DNA tests-specifically, that those tests do not distinguish between acute and persistent viral infections. Also, obtaining cervical tissue involves an invasive procedure. Although intervention during the early stages of CC yields the highest chance for cure, no current method can detect the telltale lesion(s), to our knowledge.
Tumor Markers for CC
Tumor markers such as soluble glycoproteins (which are found in serum, urine, or other body fluids and are associated with specific types of cancer) are clinically useful. The benefits of tumor markers are found in screening of people with high risk factors, diagnosis and prognosis of specific cancers, evaluation of therapeutic responses, and detection of recurrent diseases. 34 We divide tumor markers for CC screening into 2 groups, including tumor markers that are available and used commonly in laboratories and novel proteins that are involved with CC as tumor markers under investigation. Cancer antigen 19-9 (CA19-9) is associated with hepatocellular carcinoma, pancreatic adenocarcinoma, and other types of cancer. Elevated levels of CA19-9 in serum reflect an inflammatory process among epithelial cells 47 and indicate poor prognosis. 48 Moreover, CA19-9 has a role in early detection of tumor relapse in patients with CC who are undergoing radiotherapy . 49 Borras et al 50 reported that the CA19-9 level is significantly higher in patients with ADC than in those with SCC. CA19-9 is a useful marker in patients who have negative results for CA-125 in serum, despite that CA-125 is highly correlated with CC. 59 Moreover, thymidine kinase (TK) has been discovered in higher levels in patients with CC. 60 Also, plasma levels of macrophage colony-stimulating factor (M-CSF) are increased in patients with CC, and the results are comparable to other tumor markers, such as SCC-Ag and CA-125.
Tumor Markers in Clinical Use
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Since the development of monoclonal antibody and automated assays became available, several tumor markers have been discovered, such as SCC Ag, CA19-9, and CA-125. These tumor markers can be obtained from specimens obtained via minimally invasive techniques and at relatively low cost, compared with histological and molecular techniques. The results of tumor-marker testing provide quantitation of tumor tissue that reflects CC progression or treatment response. Tumor markers play an increasingly important role in cancer detection and influence management decisions of healthcare teams. Current tumor markers for CC are less than ideal because they lack strong specificity. The development of testing for tumor markers should focus on long-term stability, with combination panels for tumor markers used for most-effective diagnosis.
Epigenetics Regulation in CC
Epigenetics is the heritable change of gene expression without alteration of the DNA sequence. It affects health status and influences many diseases, including cancer. The processes of epigenetic regulation include DNA methylation, histone modification, and miRNA regulation, resulting in gene silencing and inhibition of protein synthesis. The related markers or mechanisms of epigenetic regulation might help researchers to understand the initiation and progression of CC ( Figure 1 ).
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DNA Methylation in CC
DNA methylation is the addition of methyl groups to DNA at the 5′ position of cytosine by DNA methyltransferase. Basically, this process occurs in the human genome, especially in CpG islands (short region of DNA in which the frequency of the cytosine-guanine [CG] sequence is higher than in other regions), for inhibition of gene expression. Several studies show that hypermethylation can inactivate tumor suppressor genes, causing various types of cancer. Hypomethylation can induce cell transformation via genetic instability. 63, 64 Moreover, the epigenetics of HPV viral genomes might be associated with cervical carcinogenesis. 65, 66 Increased methylation levels also correlated with severity of histological grades. 67 Expression level of methylation increased from cervical intraepithelial neoplasia (CIN) I to invasive cancer, whereas it is undetectable in normal cervical tissue. 68, 69 Therefore, these markers might serve as a new type of biomarker for CC screening, prognosis, and diagnosis ( Table 1) .
Histone Modification in CC
Histone protein, found in all kinds of eukaryotes, is classified as a basic protein that can attach to DNA via attraction to the negatively charged phosphate groups. The balancing of histone acetylation and histone deacetylation is important to gene expression. For example, histone acetylation of the HPV 16 genome induces increased HPV 16 gene expression. 70 Histone deacetylase (HDAC) is an activator of histone deacetylation and is associated with various types of cancer. 71 The overexpression of HDAC1 inhibits cell proliferation and also induces cellular senescence in CC cells. 72 The application of markers that regulate CC via histone modification are shown in Table 2 .
Understanding the pattern of expression of HDACs in each type of cancer could help in determining prognosis. Also, the occurrence of histone deacetylation in tumor suppressor genes leads to cancer progression. CC cell lines and primary tumors treated by valproate, an inhibitor of histone deacetylation, show an inhibitory effect via induction of hyperacetylation of p53, whereas no effect is shown on expression of oncoproteins such as E6 and E7. 73 Moreover, the demonstration of synergistic effect between proteasome inhibitor, bortezomib, and HDAC inhibitor and trichostatin A (TSA) or vorinostat is effective in killing HPV-positive CC cell lines. 74 Therefore, HDAC inhibitor was developed as an epigenetic therapeutic approach for specific targeting of CC. 75, 76 miRNAs to be regulated by the high-risk strains HPV 16 and HPV 18 in keratinocyte cell lines. miR-16, miR-25, miR-92a, and miR-378 were upregulated, whereas miR-22, miR-27a, miR-29a, and miR-100 were downregulated. Moreover, the results from cervical-tissue specimens also correlate with in vitro results, such that miR-25, miR-92a, and miR-378 are increased with CC cell progression. 79 Yao Q et al 80 found
that among onco-miRs, miR-21 is the most commonly overexpressed in many types of cancer. They reported that programmed cell death 4 (PDCD4) is a target of miR-21 and that overexpression of miR-21 can promote cell proliferation in HeLa cervical carcinoma cell lines. Xu J et al 81 reported
that miR-21 upregulation can cause CC to become invasive via inhibition of the phosphatase and tensin homolog (PTEN). Chemokine (C-C motif) ligand 20 (CCL20) is the target gene of miR-21, and its level is related to the stage of tumor differentiation in a mouse model. 82 Moreover, miR-21 expression is also associated with HPV infection. Its level is gradually increased in normal cells, cervicitis, and SCC-Ag, respectively. Upregulated levels of miR-21 are correlated with increased expression of IL-6 that may be involved in inflammatory processes. 83 Yamamoto et al 84 reported that miR-29a, which is a family of miR-29 classified as a candidate tumor suppressive miRNA, is targeted to heat shock protein 47 (HSP47). The result of silencing HSP47 is restraint of cell migration and invasion, as shown in 4 CC cell lines. Moreover, miR-29 also targets YY1 transcription factor (YY1) and cyclin-dependent kinase 6 (CDK6). Therefore, miR-29 inhibits cell cycle progression, and apoptosis is induced by HPV-promoting malignant transformation. 85 There is evidence to support inhibition of tumor growth via targeting adenosine triphosphate (ATP) citrate lyase by miR-22. 86 Further, a low expression level of miR-22 is associated with an increased survival rate among patients with CC. 87 A ratio of miR-25/-92a group over miR-22/-29a group of greater than 1.5 is suggested as a potential marker to separate normal cells from CC cells. 79 miR-182 is an onco-miRNA that gradually increases in serum with advancing stages. 88 The apparent mechanism is that inhibition by DNA methyltransferase 3a (DNMT3a) can cause miR-182 to induce cell apoptosis.
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Among 33 CC-tissue microarray specimens, 66.7% showed upregulation of miR-146a expression. 90 Also, miR146a and miR-21 levels are found in cervicovaginal lavage from patients with CC. 91 Moreover, miR-146a is regulated by signal transducer and activator of transcription 3 (STAT3), and inhibition of miR-46a promotes an antitumor immune response associated with several cytokines. 92 Therefore, the differential expression and function of miRNAs during CC development, and our understanding of the involved mechanisms, is likely to lead to discoveries of novel miRNAs that are useful for diagnosis, prognosis, and therapy. Results from clinical specimens that are consistent with those from CC cell lines will add support for these candidate miRNAs as powerful markers.
Early Detection of CC by Measurement of miRNAs in Blood
Discovery of new biomarkers that identify specific diseases before symptoms appear can extend the survival rate of patients. Properties of the ideal biomarker are early detection, sensitivity to changing stages of disease, minimally invasive specimen collection, no time-consuming processing, and comparable-to or better-than-standard tumor markers in clinical laboratory use. In the past, miRNAs were believed to exist within cells only; however, miRNAs are now known to be secreted into the bloodstream via granular vesicles or exosomes, where they are embedded. Recently, 2 studies 93, 94 showed the vital role that miRNAs can play in the diagnosis of several types of cancer because 60% of mammalian mRNAs are targeted by at least one miRNA.
Also, miRNA is stable in circulating blood due to its resistance to RNase degradation and can be detected in nanogram quantities. Differential miRNA expression patterns can be used to classify groups as healthy controls or patients ( Table 3) . Zhao S et al 95 report that miR-20a and miR-203 were upregulated in the serum of patients with CC but that only circulating miR20a was useful for detecting lymph-node metastasis. Elevated levels of miR-205 in serum correlated with CC tumor stage and decreased the survival rates of patients. 96 Circulating levels of miR-646, miR-141*, and miR-542-3p are statistically significantly different when assayed before and after surgical procedures. Thus, these markers might be selected for use in monitoring the health status of patients after treatment. 97 Tang BB et al documented that decreased expression levels of miR-218 in serum are similar to those from CC tissue. Moreover, miR-218 levels are also associated with tumor stage in patients. 98 Differentially expressed miRNAs in serum of patients with CC, compared with those levels in controls, determined by using Solexa sequencing, showed 12 miRNAs of interest. The 5 upregulated miRNAs were miR-21, miR-29a, miR-200a, miR-25, and miR-485-5p, and
Figure 1
Overview of markers in cervical cancer diagnosis. 
Conclusion
miRNAs have been widely studied as a result of their diverse roles in cellular processes, including proliferation, differentiation, apoptosis, and inflammation. Several miRNAs are associated with CC and might be useful for clinical application. The differences in biological properties of cell lines and primary tissue from cervical biopsy affect miRNA expression levels. Also, host genetic variation, aging, and duration and type of viral infection also impact CC susceptibility. Detection of miRNAs in circulating blood is a means for reducing the number of invasive specimen collections. To increase accuracy, profiles of miRNAs in serum need to be verified in large sample sizes.
Finally, construction of panels of candidate miRNAs from blood specimens-for use as screening, diagnostic, or prognostic markers and for prediction of risk of CC by SNP in miRNAs-are challenges for future researchers. LM
